Responses
Plenary 01: Oral Abstract Presentations
AS11. Ovarian cancer
PO003/#269 Ignite: a phase II signal-seeking trial of adavosertib targeting recurrent high grade serous ovarian cancer with cyclin E1 over-expression with and without gene amplification
Compose a Response to This Article
Other responses
No responses have been published for this article.